←Back to Expert Scholars
Translational Medicine / 转化医学TLR Agonists, Innate Immunity
Arthur Krieg
MD
🏢Checkmate Pharmaceuticals (Regeneron)🌐USA
Chief Scientific Officer
90
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Arthur Krieg discovered immunostimulatory CpG DNA and pioneered TLR9 agonist development for cancer. His intratumoral TLR9 agonists are being tested to inflame cold tumors and prime checkpoint-inhibitor responses. He is recognized as a founder of oligonucleotide-based innate immune activation.
Share:
🧪Research Fields 研究领域
TLR9 agonist
CpG oligonucleotides
innate immune activation
intratumoral immunotherapy
cold tumor inflammation
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Arthur Krieg 的研究动态
Follow Arthur Krieg's research updates
留下邮箱，当我们发布与 Arthur Krieg（Checkmate Pharmaceuticals (Regeneron)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment